A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

Insulin aspart was the second rapidly acting analogue introduced, approved for clinical use in Europe in 1999 and by the FDA in 2000 for patients with Type 1 or Type 2 diabetes. It is obtained by ...

safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI) in diabetes mellitus in the following categories: (a) in adults ...

an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart. Sanofi-Aventis' Merilog version of the product has been cleared for the treatment of adult and ...

Biocon Biologics and Civica, Inc. on Thursday announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. According to the company’s ...

According to the company, this collaboration aims to enhance access and affordability of Insulin Aspart in the US. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, stated ...

Biocon Biologics and Civica announce agreement to expand access and affordability of Insulin Aspart in the U.S. Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug ...